Cargando…

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy

BACKGROUND: Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene. METHODS: From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blanch-Lombarte, Oscar, Santos, José R, Peña, Ruth, Jiménez-Moyano, Esther, Clotet, Bonaventura, Paredes, Roger, Prado, Julia G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443716/ https://www.ncbi.nlm.nih.gov/pubmed/32556165 http://dx.doi.org/10.1093/jac/dkaa228

Ejemplares similares

Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors
por: Codoñer, Francisco M, et al.
Publicado: (2017)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses
por: Salgado, Maria, et al.
Publicado: (2018)

Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells
por: Ruiz, Alba, et al.
Publicado: (2019)

Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2023)

Enhancement of Antiviral CD8(+) T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2019)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors
por: Kilpeläinen, Athina, et al.
Publicado: (2022)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Baseline PI susceptibility by HIV-1 Gag-protease phenotyping and subsequent virological suppression with PI-based second-line ART in Nigeria
por: Datir, R, et al.
Publicado: (2019)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues
por: Clarke, Amanda, et al.
Publicado: (2014)

The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health
por: Bedimo, Roger J., et al.
Publicado: (2014)

Boosting Virology in Brazil
por: Pardini, Maria Inês de Moura Campos, et al.
Publicado: (2008)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients
por: Mata-Marín, José Antonio, et al.
Publicado: (2015)

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study
por: Mills, Anthony M., et al.
Publicado: (2019)

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study
por: Spinner, Christoph D, et al.
Publicado: (2020)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort
por: Chaussade, Hélène, et al.
Publicado: (2020)

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
por: Solana-Altabella, Antonio, et al.
Publicado: (2022)

A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes
por: Santos, José R, et al.
Publicado: (2023)

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
por: Moltó, J, et al.
Publicado: (2010)

Research alone is not sufficient to prevent sports injury
por: Hanson, Dale, et al.
Publicado: (2014)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Cobicistat/darunavir/cobicistat/darunavir/emtricitabine/tenofovir-alafenamide/darunavir/ritonavir: Various toxicities and off-label use: 9 case reports
Publicado: (2020)

Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
por: Pillay, D, et al.
Publicado: (2010)

Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial
por: Elgadi, Mabrouk M., et al.
Publicado: (2012)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

Nucleocapsid Promotes Localization of HIV-1 Gag to Uropods That Participate in Virological Synapses between T Cells
por: Llewellyn, G. Nicholas, et al.
Publicado: (2010)

Sequential trafficking of Env and Gag to HIV-1 T cell virological synapses revealed by live imaging
por: Wang, Lili, et al.
Publicado: (2019)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Risk information alone is not sufficient to reduce optimistic bias
por: Felgendreff, Lisa, et al.
Publicado: (2021)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

1766. Sustained Viral Suppression with Dolutegravir and Boosted Darunavir Dual Therapy Among Highly Treatment-Experienced Individuals
por: Hawkins, Kellie, et al.
Publicado: (2018)

Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study
por: Weidlich, Simon, et al.
Publicado: (2020)

Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing
por: Lataillade, Max, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jljt7m2jeee7bdpttiqipmpk67